- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $196.75 (6.8% Upside)
About Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read More
Recent Analyst Ratings